Abstract We studied the effect of the potent dietary antioxidant lycopene on multiple points along the nuclear factor kappa B (NF-κB) signaling pathway in prostate and breast cancer cells. Lycopene significantly inhibited prostate and breast cancer cell growth at physiologically relevant concentrations of ≥1.25 μM. Similar concentrations also caused a 30-40 % reduction in inhibitor of kappa B (IκB) phosphorylation in the cells, as determined by western blotting. Furthermore, the same degree of inhibition by lycopene was observed for NF-κB transcriptional activity, as determined by reporter gene assay. Concomitant with this, immunofluorescence staining of lycopene-treated cells showed a significant suppression (≥25 %) of TNF-induced NF-κB p65 subunit nuclear translocation. Further probing of lycopene's effects on upstream elements of the NF-κB pathway showed a 25 % inhibition of both activity of recombinant IκB kinase β (IKKβ) kinase in a cell-free in vitro assay, as well as activity of IKKβ immunoprecipitated from MDA-MB-231 cells treated with lycopene. In conclusion, the anticancer properties of lycopene may occur through inhibition of the NF-κB signaling pathway, beginning at the early stage of cytoplasmic IKK kinase activity, which then leads to reduced NF-κB-responsive gene regulation. Furthermore, these effects in cancer cells were observed at concentrations of lycopene that are relevant and achievable in vivo.
Introduction
Prostate and breast cancer are two of the most common cancers worldwide. Prostate cancer is the most common cancer in men in the UK, while breast cancer is the second most common cancer worldwide [1] . Although age and genetic factors play key roles, many studies indicate that lifestyle and diet are also significant aspects involved in cancer risk [2] . While preventative measures for both cancers are not well known, increased tomato intake, as highlighted first by the Health Professionals Follow-Up Study (HPFS) and a few other studies, has been linked to a reduced risk of prostate cancer [3, 4] . This potential chemo-preventative effect of increased tomato intake has been attributed to their richness in the red pigment carotenoid lycopene [5] [6] [7] [8] . An association between plasma levels of lycopene and reduced risk of aggressive prostate cancer was reported in the Physicians Health study, which showed a 25 % reduction in overall prostate cancer with plasma lycopene concentrations of 388 ng/ml (0.72 μM) and 44 % lower incidence of aggressive prostate cancer at plasma lycopene Electronic supplementary material The online version of this article (doi:10.1007/s13277-016-4798-3) contains supplementary material, which is available to authorized users.
concentrations of 356 ng/ml (0.66 μM) [5] . Due to its lipophilic nature, lycopene accumulates in the prostate, adrenal gland, testes, and liver [9] , which could explain its particular connection to prostate cancer risk. However, those findings led to investigations in a number of other cancer types and diseases. Although no significant link between dietary lycopene intake and breast cancer has yet been made [6, 7] , a number of studies have demonstrated its chemo-preventative effects in breast cancer cell cultures [8, [10] [11] [12] .
The putative chemo-preventative activity of lycopene may be attributed to its potent antioxidant properties, derived from an electron-rich conjugated polyene chain, making it the most effective singlet oxygen-quenching carotenoid. Thus, it is highly effective in deactivating electrophiles such as oxygen and free radicals, formed as cellular oxidative by-products, and which can cause oxidative stress and damage to cellular components [13] . Several cell culture-based investigations as well as some in vivo studies have shown lycopene to reduce DNA, protein, and lipid damage from oxidative injury [14, 15] . However, in the case of prostatic carcinoma cell lines, different studies have reported variable inhibitory efficacies of lycopene as regards cell proliferation [16] [17] [18] [19] . One study found lycopene at 1 μM to be sufficient for reducing proliferation in LNCaP cells [16] , whereas in another study using PC3, DU145, and LNCaP cells, lycopene reduced cell viability and growth only at high concentrations (20 μM) which is too high to be realistically achievable in vivo [17] . Within the physiologically relevant concentration range, no effect of lycopene was observed on LNCaP cell proliferation [18] , whilst in contrast, a decrease in DU145 cell growth was reported at particularly low concentrations (10 nM) [19] .
Therefore, there remains an uncertainty as to the actual efficacy of lycopene as an anticancer molecule at physiologically relevant concentrations. We recently showed that lycopene inhibited angiogenesis of endothelial cells at physiologically relevant concentrations [20] . In prostate cancer cells, we showed that lycopene at 1.15 μM inhibited motility of PC3 and DU145 cells by 40 and 58 %, respectively, as well as inhibiting cell adhesion at ≥1.25 μM [21] .
The redox-sensitive transcription factor nuclear factor-κB (NF-κB) controls the transcriptional activation of many fundamental genes that regulates cell proliferation, apoptosis, metastasis, angiogenesis, inflammation, cellular adhesion, and cell invasion [22] . Consequently, aberrant signaling along the NF-κB pathway is believed to mediate several major cellular processes that occur in carcinogenesis. Constitutive activation of the NF-κB pathway has been reported in several cancer cell lines [22] , including from prostate tumors [23] . Over-activity of the NF-κB pathway has been reported during the early developmental stages of prostate cancer [24, 25] , while inhibition of the NF-κB pathway was shown to reduce the malignant properties of PC3 cells [26] . Furthermore, constitutive activation of NF-κB has been linked to tumor progression in hormone-independent breast cancer cell lines such as MDA-MB-231 [27] , and breast gland development and breast carcinogenesis have been linked with NF-κB-induced cyclin D1 expression [28, 29] and selective activation of Bcl-3 and NF-κB subunits, p50 and p52 [30] . Furthermore, mutations in NFKB1, IKK2, IκBα, and IκBε have also been identified in breast cancer [31] as well as defective IκBα in solid breast tumors [32] . Therefore, therapeutic targeting of the NF-κB pathway may represent a potential and multifaceted approach to combating cancers.
Several studies have shown the ability of a variety of antioxidant compounds to suppress NF-κB signaling in reproductive cancers including ovarian [33] , breast [34] , and prostate [35] cancers. Likewise, lycopene has been shown to inhibit Ras-dependent activation of the NF-κB pathway in prostate cancer cells, resulting in cell cycle inhibition and apoptosis [36] . In SK-Hep-1 cells, lycopene reduced the binding affinity of the NF-κB transcription factor complex to MMP-9 gene promoter sequences [37] . Therefore, these clues warrant further mechanistic investigation into the effects of lycopene on the NF-κB signaling pathway in cancer cells. Importantly, whether lycopene can exert these potential effects at physiologically attainable concentrations also requires clarification. In the present study, we have conducted such an investigation, examining the NF-κB signaling pathway at multiple levels in both human prostate and breast cancer cells. Here, we report that lycopene at physiologically relevant concentrations inhibits NF-κB signaling through direct inhibition of the upstream activating kinase IKK, thus linking with suppression of the pathway observed at multiple points further downstream.
Materials and methods

Lycopene preparation
Prefiltered tetrahydrofuran (THF; Sigma-Aldrich, Poole, UK), stabilized with butylated hydroxytoluene (BHT) at 0.0025 % (w/v) to avoid peroxide formation, was used for the preparation of lycopene stock solutions, and aliquots of solution were stored in dark in amber vials at −80°C. Lycopene was a gift of DSM Nutritional Products, Basel, Switzerland. For each experiment, the concentration of stock solution of lycopene was checked using an extinction coefficient of 196,145 M/cm for a solution of lycopene in THF. Prior to treatment of cells, the stock solution was first diluted 1:10 in fetal bovine serum (FBS (Lonza, Slough, UK), which acts an effective delivery vehicle for the cellular uptake and stability of lycopene [38] . This was then further diluted in Dulbecco's modified Eagle medium (DMEM) medium (with 4.5 g/L L-glucose and Lglutamine; Life Technologies Gibco, Paisley, UK) to achieve the desired experimental concentrations (0.5-5 μM). THF/ BHT was used as a solvent vehicle control and was also prepared through further dilution in the same manner as lycopene. We found that replenishing lycopene on a daily basis, which was performed in one of our experiments (Fig. 1b) , did not alter the experimental outcomes significantly compared to when the replenishment step was omitted.
Cell culture
Two human cancer cell lines were used in this investigation: PC3 cell line and MDA-MB-231 cell line. The PC3 cell line is androgen-independent, highly malignant, pro-metastatic, and is an established human prostate cancer cell line that was initiated from a bone metastasis of a 62-year-old Caucasian. The MDA-MB-231 cell line is also pro-metastatic, estrogen receptor negative, and initiated from a breast metastasis of a 51-year-old female Caucasian. Both cell lines were purchased from European Collection of Cell Cultures (ECACC) in 2013 and were authenticated in-house by short tandem repeat (STR) analysis as previously described [39] . Cells were maintained in culture in complete medium composed of DMEM supplemented with 10 % FBS and 1 % penicillin/streptomycin (Lonza). Cells were incubated at 37°C in a humidified atmosphere of 5 % CO 2 in air. Cells were seeded at 0.5 × 10 3 for MTS assays in 96-well plates. Cells were seeded at concentrations of 1 × 10 4 cells/ml and 3 × 10 3 cells/ml in 24-well plates, for western blot and luciferase assay, respectively. Cells used for immunoprecipitation (IP) were plated in 100-mm dishes and treated once 80-90 % confluence was reached. A cocktail of phosphatase inhibitors (Sigma-Aldrich), calyculin A, and sodium orthovanadate was added to cell lysates for all downstream applications.
MTS cell growth assay
Cell survival/growth in the presence of lycopene (0.5-5 μM, 48 h) was measured using the colorimetric MTS assay method. MTS tetrazolium compound (CellTiter 96 ® Aqueous MTS r e a g e n t ( 3 -( 4 , 5 -d i m e t h y l t h i a z o l -2 -y l ) -5 -( 3 -carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt); Promega, Southampton, UK) was mixed with phenazine methosulfate (PMS; Sigma-Aldrich) to form MTS assay reagent. MTS-PMS complex (20 μL) was added per well to the 96-well plates at the end of the incubation periods with test agents. The catalytic activity of viable cells results in formazan dye production, which is then quantified. Cells were incubated with the dye for 1 h, followed by absorbance reading at 492 nm on a spectrophotometer (BioTek, Potton, UK).
Western blot
Cells were seeded into tissue culture multiwell plates, and on the following day, the growth medium was replaced with serum-free medium containing various concentrations of either lycopene (1.25-5 μM) or THF as vehicle control. The cells were incubated further for 20 h. Recombinant human TNFα (R&D Systems, Abingdon, UK) was added to cells at 40 ng/ml 30 min prior to lysis for use as a positive control inducer of the NF-κB pathway. Cells were washed with icecold phosphate-buffered saline (PBS) and lysed in 75 μl/well lysis buffer (150 mM NaCl, 1 % Triton X-100, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 50 nM Tris pH 8.0) containing protease and phosphatase inhibitor cocktail (Sigma-Aldrich), calyculin A, and sodium orthovanadate. Cell lysates were removed from the well and Values are mean ± SEM of optical density (quadruplicate wells per treatment; four independent experiments). *p < 0.05; lycopene versus THF at 48 h clarified by centrifugation at maximum speed in a microfuge for 10 min at 4°C. The soluble cell extracts were loaded and separated by 10 % SDS-polyacrylamide gel electrophoresis (SDS-PAGE), alongside a molecular weight marker sample spanning the 10-250 kDa range (PageRuler Plus prestained protein ladder; Thermo Scientific, Loughborough, UK). Separated proteins on the gels were transferred to an activated PVDF membrane (Immun-Blot ® ; Bio Rad, Hercules, CA) using a fast semidry protein transfer method (Pierce G2 Fast Blotter and 1-Step Transfer Buffer; Thermo Scientific). Membranes were first incubated in blocking buffer (TBS-Tween 20 wash buffer containing 3 % BSA) for 1 h at room temperature, with the exception of blots probed for phosphorylated IκBα (p-IκBα), which were not blocked so as to avoid over-quenching of the signal. Membranes were incubated with primary antibody overnight at 4°C, following which they were washed 3 × 5 min in wash buffer, and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 2 h at room temperature. Primary antibodies that had been characterized and reported in previous studies were used at recommended dilutions as follows: rabbit anti-p-IκB-α (Ser 32/36) (Cat. No. sc-101713, Santa Cruz Biotechnology, Heidelberg, Germany) [40] and anti-actin rabbit polyclonal (Cat. No. A2066-.2ML) (Sigma-Aldrich) [41] . Secondary antibody was HRP-conjugated swine anti-rabbit Ig (Product No. p021702-2, Dako, Glostrup, Denmark) [42] . After washing, the membrane was developed by incubation with an enhanced chemiluminescence reagent followed by imaging of the blot under a CCD camera imaging system (G:BOX Chemi XL1.4, Syngene, Cambridge, UK).
Cell fixing and immunofluorescence staining
MDA-MB-231 and PC3 cells were seeded onto coverslips placed in 6-well culture plates. Cells at ∼60 % confluence were serum-starved overnight, after which they were pretreated with lycopene (5 μM) or THF vehicle for 2 h. Cells were then stimulated with TNFα (40 ng/ml) over a time course of 1-5 h. Cells were fixed with 4 % paraformaldehyde diluted in PBS and then permeabilized with 0.2 % Triton X-100 diluted in PBS; 2 × 5 min PBS washes were performed in between fixing and permeabilization. Cells were blocked for 1 h at room temperature with 10 % horse serum diluted in PBS, followed by 1 × 5 min PBS wash. Cells on coverslips were incubated with rabbit polyclonal NF-κB p65 primary antibody (C-20; Santa Cruz) [43] for 1 h at room temperature. The secondary antibody was Alexa Fluor 488-conjugated donkey anti-rabbit IgG (A-21206; Life Technologies) [44] , incubated for 1 h at room temperature in the dark. Washes (3 × 5 min) were performed between antibody incubation stages. Cells were mounted onto microscope slides using Vectashield (Vector Laboratories, Burlingame, CA). Images were obtained using a fluorescence microscope (FSX100; Olympus, Southend-on-Sea, UK).
NF-κB-responsive gene activation reporter assay
The NF-κB activity level in cell lysates at the level of NF-κB-responsive gene expression was measured by luciferase-based reporter assay (Promega dual-luciferase® reporter assay system). The firefly luciferase reporter plasmid contains five copies of an NF-κB response element (PGL4.32[luc2P/NF-κB-RE/Hygro] vector; Promega). This plasmid drives transcription of the luciferase reporter gene luc2P (Photinus pyralis). Cell treatment incubation time for luciferase assay lysates was approximately 72 h and did not include a serum starvation period. Each concentration of lycopene (0.5-5 μM) had an equivalent dilution of THF as matched control. Cells were transfected 24 h after plating with firefly and transfection control Renilla luciferase reporter plasmids using jetPRIME® transfection reagents according to manufacturer's protocol (Polyplus, Nottingham, UK). Cells were incubated with transfection reagent mixed with firefly and transfection control Renilla luciferase reporter plasmids and 72 h later were washed with PBS and lysed with luciferase assay lysis buffer (Promega). Luciferase levels were measured for 10 s using a luminometer (1450 microbeta, PerkinElmer, Seer Green, UK). Background readings of untransfected control lysates were subtracted from luminescence values. Values were normalized against positive transfection control (Renilla luciferase).
Immunoprecipitation
Once cells reached 80-90 % confluence in 100-mm dishes, cells were treated accordingly, by incubation overnight with THF, lycopene, and staurosporine (10 nM) as an IKK inhibitor positive control. Cells were washed with ice-cold PBS and lysed with 1 ml Pierce IP lysis buffer (Thermo Scientific) per dish. Cell lysates were clarified by centrifugation and precleared with 10 μl protein A/G-agarose beads (Santa Cruz) 1 h at 4°C with constant rotation. Lysates were then incubated with 2 μg anti-IKKβ rabbit polyclonal (Cat. No. SAB1300467-100UG) [45] 1 h on ice. Anti-Trx rabbit polyclonal antibody (Santa Cruz) was used as a negative control pulldown antibody. After this, 10 μl protein A/G-agarose beads was added to each sample and incubated further for 1 h at 4°C with constant rotation. Beads were pelleted by centrifugation at 8000×g for 1 min and the supernatant removed. Beads were washed by suspension in ice-cold IP lysis buffer followed by centrifugation at 8000×g for 1 min, repeated three times, discarding the supernatant each time.
In vitro IκB kinase activity assay
The IκB kinase β (IKKβ) Kinase Enzyme System and ADP-Glo™ Kinase assay were performed according to the manufacturer's instructions for each assay (Promega) in 96-well plates. The bead pellet obtained from immunoprecipitation of IKKβ was washed a final time with IKK reaction buffer (8000×g for 1 min), discarding the supernatant. The ADP-Glo™ Kinase assay reaction buffer containing ATP (25 μM) and the IKKβ substrate peptide IKKtide (0.2 μg/μl) (Promega) were added directly to the pellet, and the kinase reaction incubated for 1 h at room temperature, to allow IKK to convert ATP to ADP. After this, the beads were centrifuged (8000×g for 1 min) to separate them from the supernatant, to be used for western blot analysis (see above). Subsequent probing of the pulldowns with the anti-IKKβ antibody in western blot revealed that the IKKβ IPs from each sample were successful and even. The supernatant was added to a 96-well plate, and ADP-Glo™ reagent (Promega) was added to the wells and incubated at room temperature for 40 min, to halt the kinase reaction and deplete any remaining ATP. Kinase detection reagent was then added to wells and left to incubate for a final 30 min at room temperature. This final step converts ADP to newly synthesized ATP via a luciferase reaction. The same assay was also performed in a cell-free system. One hundred nanograms recombinant IKKβ (Sigma-Aldrich) was preincubated with lycopene (5 μM) and assay reagents for 1 h. The reaction was then induced and incubated with IKKtide for a further hour. Luminescence was read using a microplate reader (BMG Labtech Fluorstar Optima, Offenburg, Germany).
Statistical analysis
ImageJ software (http://imagej.nih.gov/ij/) was used to perform densitometric analysis of relative nuclear/ cytoplasmic ratio of immunostained cells and western blot protein bands, and density values of bands of interest were normalized against those of bands for actin. Paired t test was used for pairwise analysis of THF-and lycopenetreated cells at varying concentrations; a p value ≤0.05 was considered statistically significant. One-way ANOVA with Tukey post hoc test was used for dose-response values. Prism software (GraphPad, La Jolla, CA) was used for all statistical analyses.
Results
Lycopene inhibits proliferation in PC3 and MDA-MB-231 cells
We began our investigation by studying the effect of lycopene on the proliferation of prostate cancer cells. We found that incubation of PC3 and MDA-MB-231 cells for 48 h with lycopene (0.5-5 μM) caused a concentrationdependent decrease in growth of both cell lines, relative to THF vehicle (ANOVA, p < 0.05), DU145 (p < 0.0001), and PC3 (p < 0.001) versus control from 1.25 μM concentration upwards (Fig. 1a) . We found that the growth inhibitory effect of lycopene was significant only after incubation with cells for 48 h. MDA-MB-231 cells that were treated with lycopene (5 μM) or THF for 24 h showed no significant differences in growth, whereas 48-h incubation with lycopene resulted in an approximately 16 % reduction versus THF (paired t test, p < 0.05) (Fig. 1b) .
Lycopene inhibits IκB phosphorylation in PC3 and MDA-MB-231 cells
To determine whether lycopene has an effect on NF-κB signaling pathway, we initially investigated its effect on phosphorylation of inhibitor of kappa Bα (IκBα). PC3 and MDA-MB-231 cells were serum-starved and treated for 20 h with a range of concentrations of lycopene (1.25-5 μM) or THF solvent vehicle. We employed western blotting technique and found that in both cell lines, a 30-40 % reduction in p-IκBα protein levels was observed in lycopene-treated cells relative to THF. This effect was significant at all concentrations tested (1.25-5 μM) (Fig. 2a) . Furthermore, lycopene also significantly inhibited p-IκBα protein levels in both cancer cell lines pretreated for 30 min with TNFα in a concentrationdependent manner ( Fig. 2b; Suppl Fig. S1 ). Therefore, lycopene inhibited NF-κB signaling in prostate cancer cells at the level of IκBα phosphorylation by IKK, under both basal and TNF-stimulated conditions (paired t test, *p < 0.05 vs THF). We initially included a third cell line (human epithelial prostate cell line PNT2); however, p-IκBα protein levels in this non-tumor cell line were too low to be detected (data not shown).
Lycopene inhibits TNFα-induced NF-κB p65 nuclear translocation in MDA-MB-231 and PC3 cells
We then tested if the inhibition of IκBα phosphorylation by lycopene was concomitant with a decrease in NF-κB nuclear translocation. To determine this, we performed immunofluorescence staining for the NF-κB p65 subunit (Fig. 3) . MDA-MB-231 and PC3 cells were serum starved overnight and then treated with lycopene (5 μM) or THF vehicle the next day for 2 h. Following this, p65 nuclear translocation was induced in cells with TNFα (40 ng/ml) over a time course of 1-5 h. A peak effect by TNFα was found to occur at 2 h in both cell lines (MDA-MB-231, Fig. 3a; PC3 Fig. 3b) where the p65 nuclear/cytoplasmic ratio was ∼2.5× greater than basal levels. Lycopene significantly suppressed p65 nuclear translocation from 2 to 5 h by at least ∼25 %, which almost mirrored basal levels in the presence of THF vehicle and absence of TNFα stimulation. The most significant effect of lycopene in both cell lines also occurred at 2 h, where p65 nuclear translocation was inhibited by approximately ∼60 % compared to cells in vehicle only (paired t test, *p < 0.05 vs THF).
Lycopene inhibits NF-κB transcriptional activity in MDA-MB-231 and PC3 cells
We investigated whether the inhibition of p65 nuclear translocation caused by lycopene occurred at a transcriptional level downstream of the NF-κB pathway. For this, we utilized a NF-κB-responsive gene activation reporter assay. PC3 and MDA-MB-231 cells were treated with a range of concentrations of lycopene (0.5-5 μM) or THF solvent vehicle alone for 72 h. Incubation of prostate cancer cells with lycopene caused a concentration-dependent decrease in NF-κB transcriptional activity, with reductions of 20-40 and 20-50 % in MDA-MB-231 (p < 0.05) and PC3 cells (p < 0.001), respectively, in comparison to cells incubated with vehicle at the same dilutions (Fig. 4) . The inhibitory effects were significant starting from 1.25 μM (ANOVA, p < 0.05), with 0.5 μM lycopene showing no significant effect.
Lycopene reduces IKKβ kinase activity in a cell-free system and in intact MDA-MB-231 cells Finally, we examined whether lycopene's inhibitory effect on the NF-κB pathway also occurred at an upstream level by studying its effect on IKKβ kinase activity. We tested this in a cell-free system as well as using MDA-MB-231 cells. Pure recombinant IKKβ was preincubated with 5 μM lycopene or THF solvent for 1 h, then a further incubation for 1 h in the presence of IKKtide substrate. Lycopene reduced IKKβ kinase activity by ∼25 % when compared to THF control (p < 0.01) (Fig. 5a) . Similarly, IKKβ from MDA-MB-231 cells treated overnight (∼15 h) with lycopene (5 μM) showed a reduction in activity by ∼25 % (Fig. 5b) compared to THFtreated cells. A vehicle effect was observed in both cell-free system and in MDA-MB-231 cells; THF reduced IKKβ kinase activity by ∼20 %. Staurosporine (10 nM) reduced IKKβ activity in cells by ∼25 % compared to baseline levels and by ∼40 % in the presence of THF. This indicates that although there was a vehicle effect, this did not mask the effect of either lycopene or staurosporine. Therefore, these data indicate that lycopene directly acts to inhibit IKKβ kinase activity. 
Discussion
In this study, we have investigated the effects of lycopene specifically on the NF-κB signaling pathway. Here, we demonstrate that lycopene acts via inhibiting NF-κB signaling, the influence of which have observed at multiple levels along the pathway. MTS proliferation assays showed that lycopene reduced proliferation in both PC3 and MDA-MB-231 prostate cancer cells, which was apparent only after 48-h incubation. The inhibition was concentration-dependent, including concentrations that are physiologically relevant (1.25-5 μM). A conceivable mechanism for this growth inhibition is through the induction of cell cycle arrest and apoptosis [14, 30, [46] [47] [48] . Several studies have previously reported lycopene to inhibit growth of prostate cells, including DU145, LNCaP, and human prostate epithelial cells [14, 48, 49] . Additionally, studies using MCF-7 breast cancer cell line have also noted antiproliferative activity from lycopene [11, 50] .
We found that 20-h incubation with lycopene reduced phosphorylation of IκBα by approximately one third in both PC3 and MBA-MD-231 cells. This effect occurred both in the absence and presence of TNFα, a strong inducer of the NF-κB pathway [22] . The phosphorylation of IκBα occurs early in the NF-κB pathway, by which it instigates activation of this signal pathway, releasing NF-κB from sequestration by IκBα, and permitting translocation of NF-κB to the nucleus, hence driving target gene expression [22] . This therefore demonstrates that lycopene interferes with an early event in the NF-κB pathway, specifically the stage where IKK phosphorylates IκBα and thereby affects the cellular localization of NF-κB. The inhibition of IκBα phosphorylation occurred at all concentrations tested, including the lowest concentration (1.25 μM), which is an achievable physiological concentration of lycopene that has been measured in the blood [51, 52] . Furthermore, the maximum effect was observed at 2.5 μM; a higher concentration of 5 μM did not increase the effect. This effect was concomitant with lycopene's influence on nuclear translocation of NF-κB p65 subunit. We found that lycopene (5 μM) was able to dramatically inhibit TNFα-induced p65 nuclear translocation by as much as ∼60 % in MDA-MB-231 and PC3 cells. A similar effect has also been reported in LPS-stimulated murine dendritic cells, where lycopene (10 μM) was shown to suppress nuclear translocation of p65 [53] . We also probed the influence of lycopene on the downstream effects of the NF-κB pathway, where we employed a luciferase reporter assay to determine the transcriptional activity of cells bearing an NF-κB responsive promoter. In this experiment, we uncovered that lycopene inhibited the NF-κB pathway (∼20-40 %) in a concentration-dependent manner in both cell lines tested, which was consistent with our findings for upstream IκBα phosphorylation. This effect was most evident from concentrations 1.25 μM and upwards.
Finally, we investigated the influence of lycopene on IKK, an upstream component of the activation of the NF-κB pathway. The IKK enzyme complex phosphorylates IκBα in response to inflammatory stimuli such as TNFα and lipopolysaccharide (LPS) [54] . There is evidence for a correlation between inflammation and prostate cancer [55, 56] and that cytokine-induced activation of IKK is majorly involved in NF-κB pathway activation [57] [58] [59] [60] [61] [62] [63] . Furthermore, there are also high levels of of IKK-i/IKKε and kinase activity in multiple breast cancer cell lines compared to MCF-10F breast epithelial cells [64] and increased IKKα and IKKβ activity in breast cancer cells and tumor specimens [65] . We employed an enzyme activity assay to observe the effects of lycopene on IKKβ activity. We found that lycopene (5 μM) significantly reduced IKKβ kinase activity by ∼25 % compared to vehicle in a cell-free system. This indicates a direct interaction between the IKKβ enzyme complex and lycopene. We then tested if a similar effect was achievable in whole prostate cancer cells. IKKβ obtained from MDA-MB-231 cells treated with lycopene (5 μM) ∼15 h showed reduced kinase activity by ∼25 % compared to cells treated with THF. Therefore, these data confirm that lycopene directly inhibits the activity of IKKβ and that this can also occur within prostate and breast cancer cells in vivo. While we have observed inhibition by lycopene of the NF-κB pathway in prostate and breast cancer cells at different levels, our data indicate that lycopene acts at an early stage in the pathway. Lycopene inhibits phosphorylation of IκBα by reducing IKK activity in the cytoplasm. This then has the expected consequence of a reduced translocation of NF-κB into the nucleus and hence reduced NF-κB-responsive gene regulation. Recently, one study has found that 1-h incubation with synthetic lycopene derivatives reduces TNFα induced NF-κB activity in T47D mammary carcinogenic cells and osteoblasts (MC3T3 and HOS) [60] . A preparation of intact lycopene (2.7 μM) with part-oxidized lycopene and derivatives resulted in 20-30 % TNFα-induced NF-κB activity inhibition. Furthermore, 1-h incubation with lycopene derivatives (∼6-10 μM) resulted in attenuated p-IκB protein levels and IKKβ activity. However, this study found that intact lycopene alone did not have any inhibitory effect.
Our results showing lycopene suppression of the NF-κB pathway are in keeping with the role of lycopene as a potent antioxidant alongside several other antioxidants that have also been shown to act as NF-κB inhibitors, such as melatonin [33] , grape seed extract [34] , and nobiletin [35] . However, rather than through free radical scavenging, most of these antioxidants could possibly be acting in vivo through the ubiquitin proteasome system. Specifically, a target of lycopene could be the Keap1-Cul3-Rbx ligase complex, which ubiquitinates IKK and prepares it for degradation by the proteasome [66] . Under oxidative stress, or possibly through Keap1 mutations in certain cancers, Keap1 is modified and releases IKK, thus allowing it to phosphorylate IκB and activate the NF-κB pathway. Therefore, in addition to targeting IKK activity, lycopene may be causing dysregulation of the Keap1-mediated IKK ubiquitination process, thereby preventing NF-κB activation and subsequent tumor progression.
It is also possible that antioxidants such as lycopene could be acting directly on the Keap1 complex. Keap1 is also a sensor of oxidative stress through its interaction with the major antioxidant gene regulator Nrf2 [66] [67] [68] . Under stress conditions, Nrf2, which is a transcription factor, is released from Keap1 and translocates to the nucleus, where it binds to the antioxidant response element (ARE) and stimulates expression of antioxidative gene products that protect the cell [66, 67] . Lycopene has previously been shown to activate Nrf2 [69] and therefore could be doing this via the Keap1 complex. In addition, as the Keap1 complex appears to perform a pro-tumorigenic role through its concomitant activation of NF-κB signaling and repression of Nrf2-ARE signaling, Keap1 may represent an attractive therapeutic target in cancer [70] . Therefore, the targeting of Keap1 by lycopene confers an added advantage to lycopene beyond its recognized free radical scavenging functions.
The results from our study indicate that lycopene has an inhibitory effect on NF-κB signaling at concentrations ≥1.25 μM. A lower concentration of 0.5 μM had no effect, which may explain why in previous studies lycopene failed to show significant protective effects in cancer patients at plasma lycopene concentrations of ∼0.60 μM [61, 62] . Plasma levels of lycopene can be raised easily with the consumption of processed tomatoes to 1.2 μM [63, 71, 72] and with one paper reporting an increase of up to 2.1 μM [73] . One study looking at the effect of tomato paste on cultured PC3 cells and nude mice with PC3 xenografts fed on a Western-like diet with 10 % tomato paste for 6.5 weeks reported an inhibition of NF-κB activity, lycopene accumulation in the xenografts, and modulation of cancer and immune-related genes [74] . Therefore, lycopene intervention studies of cancer patients should aim for raising the plasma lycopene levels above 1 μM, and nutritionists should be looking into ways of increasing the bioavailability of lycopene from food/ supplements so that plasma levels can be easily raised above 1.25 μM.
This study helps to expand our understanding of the chemo-preventative attributes of lycopene and provides further explanation of reduced risk of prostate cancer and decreased prostate and breast tumor aggression in those with higher dietary intake of tomato products. The putative properties of this compound provide grounds for future research into its clinical usefulness, as there are currently too few clinical investigations that have examined the effectiveness of lycopene in prostate cancer patients. Therefore, this, and the fact that our study has shown effectiveness of lycopene at physiological concentrations, warrants the need for further investigation in regards to its clinical efficacy. Furthermore, this study is the first to use prostate and breast cancer cells, with lycopene tested at physiological concentrations.
In conclusion, we have shown in this study that lycopene inhibits the NF-κB signaling pathway at multiple levels in human prostate and breast cancer cells in vitro. Therefore, our data indicate the possibility that physiologically relevant levels of plasma lycopene, achievable through diet supplementation, could act through suppression of the NF-κB pathway in prostate and breast tumors in patients. Further, translational studies are required to determine this phenomenon in the clinical scenario.
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